TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 991103

Group type: EXPERIMENTAL
Intervention: Intermittent combination chemotherapy with cyclophosphamide, methotrexate, and 5-fluourouracil (CMF)
Number of subjects: 184

Group type: COMPARATOR
Intervention: L-phenylalanine mustard (L-PAM)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: CMF
Number of subjects: 184
Study: 30998121

Group type: EXPERIMENTAL
Intervention: 20% albumin
Number of subjects: 6

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 6

Group type: COMPARATOR
Intervention: Hartmann's solution
Number of subjects: 6

Group type: COMPARATOR
Intervention: 4% albumin
Number of subjects: 6

Group type: COMPARATOR
Intervention: 30 ml/kg of 0.9% saline, Hartmann's solution, and 4% albumin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Colloids (including 20% albumin)
Number of subjects: 6
Study: 25726942

Group type: EXPERIMENTAL
Intervention: Intraprocedural thrombotic events (IPTE)
Number of subjects: 1307
Study: 22936724

Group type: EXPERIMENTAL
Intervention: Anabolic steroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucocorticoids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IGF-I stimulation
Number of subjects: 0
Study: 20884100

Group type: EXPERIMENTAL
Intervention: Plant sterols (PS)
Number of subjects: 67
Study: 19083472

Group type: EXPERIMENTAL
Intervention: Whey protein (WY) 15 g
Number of subjects: 15

Group type: COMPARATOR
Intervention: Essential amino acids (EAA) 6.72 g
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nonessential amino acids (NEAA) 7.57 g
Number of subjects: 15
Study: 16510062

Group type: EXPERIMENTAL
Intervention: Topical allylamine antifungals (naftifine, terbinafine, butenafine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical azole antifungals (clotrimazole, econazole, ketoconazole, oxiconazole, miconazole, sulconazole)
Number of subjects: 0
Study: 14765003

Group type: EXPERIMENTAL
Intervention: OCD participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both patients and controls
Number of subjects: 0
Study: 10894274

Group type: EXPERIMENTAL
Intervention: Lamivudine therapy for 44-52 weeks
Number of subjects: 13
Study: 8823239

Group type: EXPERIMENTAL
Intervention: Dezocine (7.5 to 60 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Naloxone (0.1 and 0.2 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Hydromorphone (5 and 10 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 6
Study: 1294638

Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 6466933

Group type: EXPERIMENTAL
Intervention: 3' protocol with incline increments of 1.5%
Number of subjects: 10

Group type: COMPARATOR
Intervention: Other treadmill protocols (motorised and non-motorised)
Number of subjects: 10
Study: 28841028

Group type: EXPERIMENTAL
Intervention: Pre-hospital ticagrelor treatment
Number of subjects: 1456

Group type: EXPERIMENTAL
Intervention: Complete ST-segment resolution post-percutaneous coronary intervention
Number of subjects: 1456

Group type: EXPERIMENTAL
Intervention: Time from symptoms to pre-hospital electrocardiogram
Number of subjects: 1456

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 1456
Study: 28969431

Group type: EXPERIMENTAL
Intervention: HIV-DNA 600 μg (n=10)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: HIV-DNA 1200 μg (n=10)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo saline injections (n=4)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: After first HIV-MVA boost
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: After second HIV-MVA boost
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: HIV-DNA vaccine (both doses)
Number of subjects: 24
Study: 27861335

Group type: EXPERIMENTAL
Intervention: Isotonic saline infusion (2L over 4 hours)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: ACEi + Regular Sodium (RS) diet
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Add-on Hydrochlorothiazide (HCT)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Low Sodium (LS) diet
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Combination of HCT and LS diet
Number of subjects: 57

Group type: COMPARATOR
Intervention: ACEi + RS treatment
Number of subjects: 57
Study: 24295662

Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined modality using chemotherapy and concurrent radiation
Number of subjects: 0
Study: 23154315

Group type: EXPERIMENTAL
Intervention: Audio computer-assisted self interview
Number of subjects: 4049

Group type: COMPARATOR
Intervention: Face-to-face interview
Number of subjects: 4049

Group type: COMPARATOR
Intervention: Self-administered paper interview
Number of subjects: 4049
Study: 21240149

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 17596121

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (3.7 g of n‐3 long‐chain PUFAs/day)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo supplement
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 98
Study: 16305004

Group type: EXPERIMENTAL
Intervention: CaviStat-containing dentifrice
Number of subjects: 726

Group type: COMPARATOR
Intervention: Fluoride toothpaste (control)
Number of subjects: 726
Study: 11966630

Group type: EXPERIMENTAL
Intervention: EMG biofeedback (group A, 28 men)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Verbal instructions (group B, 14 men)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 42
Study: 10326116

Group type: EXPERIMENTAL
Intervention: 500 mg twice daily of nitazoxanide
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 1000 mg twice daily of nitazoxanide
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 7704961

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 4 mg orally
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 2145744

Group type: EXPERIMENTAL
Intervention: Recombinant tissue-type plasminogen activator (rt-PA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional therapy (no thrombolytic therapy)
Number of subjects: 30
Study: 388398

Group type: EXPERIMENTAL
Intervention: tienilic acid
Number of subjects: 675

Group type: COMPARATOR
Intervention: hydrochlorothiazide
Number of subjects: 675

Group type: COMPARATOR
Intervention: probenecid
Number of subjects: 675

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 675
Study: 30285506

Group type: EXPERIMENTAL
Intervention: Short-pulsed intense pulsed light (IPL)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Pulsed dye laser (PDL)
Number of subjects: 9
Study: 28063938

Group type: EXPERIMENTAL
Intervention: BCV 100 mg (2 mg/kg if <50 kg) twice weekly (BIW)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: BCV 200 mg (4 mg/kg if <50 kg) once weekly (QW)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: BCV BIW
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: BCV QW
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: BCV BIW (post hoc analysis)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (post hoc analysis)
Number of subjects: 48
Study: 25962930

Group type: EXPERIMENTAL
Intervention: Trophic breast milk feeds (10 mL/kg/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Nil per os (NPO)
Number of subjects: 27
Study: 23810841

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (1400 IU and 14,000 IU)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Placebo oil
Number of subjects: 338
Study: 21906798

Group type: EXPERIMENTAL
Intervention: Commercial programme (Weight Watchers)
Number of subjects: 772

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 772
Study: 19706085

Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide 0.01% oil applied twice daily for 4 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide 0.01% oil
Number of subjects: 32
Study: 16900233

Group type: EXPERIMENTAL
Intervention: Exercise group (n = 21) trained on a bicycle ergometer 4 times/week, 1 h/session, at 80% of their physical working capacity for 8 weeks.
Number of subjects: 38
Study: 15039494

Group type: EXPERIMENTAL
Intervention: Adalimumab plus methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus methotrexate
Number of subjects: 0
Study: 11731186

Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogens (0.625 mg)/micronised progesterone (200 mg)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Combined interventions (HRT + Pravastatin)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 37
Study: 9159675

Group type: EXPERIMENTAL
Intervention: Temporal incision (1.0 mm behind the surgical limbus)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Incision at the 12 o'clock position
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Limbal incision at the 12 o'clock position
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Incision depth of 500 microns
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Incision depth of 300 microns
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Temporal scleral incisions
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Limbal incisions at the 12 o'clock position
Number of subjects: 180
Study: 7805700

Group type: EXPERIMENTAL
Intervention: Piroxicam beta‐cyclodextrin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plain piroxicam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Piroxicam beta‐cyclodextrin sachets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Piroxicam beta‐cyclodextrin (tablet and sachet formulations)
Number of subjects: 0
Study: 3815764

Group type: EXPERIMENTAL
Intervention: Taurine (6 g for 7 days)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 29191815

Group type: EXPERIMENTAL
Intervention: Behavioural intervention to reduce STI incidence
Number of subjects: 330
Study: 27640303

Group type: EXPERIMENTAL
Intervention: Diabetes self-management education (DSME)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 85
Study: 25682463

Group type: EXPERIMENTAL
Intervention: Free gingival graft
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (spontaneous healing)
Number of subjects: 10
Study: 22828945

Group type: EXPERIMENTAL
Intervention: Rimonabant
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: COMPARATOR
Intervention: Hypocaloric diet
Number of subjects: 37
Study: 20850152

Group type: EXPERIMENTAL
Intervention: Hexaminolevulinate fluorescence cystoscopy
Number of subjects: 814

Group type: COMPARATOR
Intervention: White light cystoscopy
Number of subjects: 814
Study: 18515890

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) plus treatment as usual
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Family intervention plus treatment as usual
Number of subjects: 301

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 301
Study: 15893181

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 3745

Group type: COMPARATOR
Intervention: Pravastatin 40 mg
Number of subjects: 3745
Study: 12668787

Group type: EXPERIMENTAL
Intervention: Combined inhalation of nitric oxide and oxygen
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oxygen alone
Number of subjects: 40
Study: 10697255

Group type: EXPERIMENTAL
Intervention: Allergy Control Covers (ACC)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High Efficiency Particulate Filters (HEPA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 7548496

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (250 mg once a day for 3 days)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Tetracycline (500 mg four times a day for 3 days)
Number of subjects: 202
Study: 1940257

Group type: EXPERIMENTAL
Intervention: Silibinin 100 mg/kg body weight i.p. for 7 days
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Silibinin 50 mg/kg body weight i.p. for 7 days
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Silymarin 420 mg per day for 30 days
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 7282067

Group type: EXPERIMENTAL
Intervention: penicillin and streptomycin
Number of subjects: 60

Group type: COMPARATOR
Intervention: clindamycin and gentamycin
Number of subjects: 60
Study: 30126064

Group type: EXPERIMENTAL
Intervention: Admission cardiotocography (ACTG)
Number of subjects: 3034

Group type: COMPARATOR
Intervention: Intermittent auscultation (IA)
Number of subjects: 3034
Study: 28106354

Group type: EXPERIMENTAL
Intervention: Ropivacaine (20 mL of 0.5%) + Dexmedetomidine (1 µg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ropivacaine (20 mL of 0.5%)
Number of subjects: 60
Study: 25582310

Group type: EXPERIMENTAL
Intervention: LigaSure™ Small Jaw (LSJ)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Clamp-and-tie (CT)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Both LSJ and CT
Number of subjects: 190
Study: 24016068

Group type: EXPERIMENTAL
Intervention: Regular exercise and carrying rs1042718 minor allele
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Regular exercise and carrying rs1042718 or rs1042719 minor allele
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Social-leisure activities and carrying rs1042719 minor allele
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Carrying rs1042718 or rs1042719 minor alleles
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Interaction between negative emotion and carrying rs1042718 or rs1042719 minor allele
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Regular exercise and social-leisure activities
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Negative emotion
Number of subjects: 877
Study: 21051752

Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 173

Group type: COMPARATOR
Intervention: CNI
Number of subjects: 173
Study: 19032505

Group type: EXPERIMENTAL
Intervention: Integrated Health Programme (twice weekly during working hours, including physical exercise, stress management training, health information, and workplace examination)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Integrated Health Programme
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (offered the same intervention after the project)
Number of subjects: 40
Study: 18018351

Group type: EXPERIMENTAL
Intervention: Evidence-based medicine (EBM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 15013730

Group type: EXPERIMENTAL
Intervention: Concurrent Treatment (randomly intermixed presumed easy and hard teaching tasks)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Concurrent Treatment
Number of subjects: 4
Study: 11680444

Group type: EXPERIMENTAL
Intervention: Estradiol therapy (1 mg of estradiol-17beta per day)
Number of subjects: 664

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 664
Study: 9129469

Group type: EXPERIMENTAL
Intervention: Introduction of complementary foods at 4 months with ad libitum breast-feeding from 4 to 6 months (SF)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Continued full breast-feeding until 6 months (FBF)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Introduction of complementary foods at 4 months with maintenance of baseline breast-feeding frequency from 4 to 6 months (SF-M)
Number of subjects: 141
Study: 7930337

Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale (GDS)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Brief Carrol Depression Rating Scale (BCDRS)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Short Geriatric Depression Scale (SGDS)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Center for Epidemiologic Studies Depression Scale (CES-D)
Number of subjects: 134
Study: 3349550

Group type: EXPERIMENTAL
Intervention: 150 ml coffee with oral ranitidine 150 mg (Group 4)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 150 ml orange juice with oral ranitidine 150 mg (Group 5)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: oral ranitidine alone (Group 6)
Number of subjects: 300
Study: 30304656

Group type: EXPERIMENTAL
Intervention: Early strategy for renal-replacement therapy (within 12 hours after documentation of failure-stage acute kidney injury)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Delayed strategy for renal-replacement therapy (after a delay of 48 hours if renal recovery had not occurred)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Delayed strategy for renal-replacement therapy
Number of subjects: 488
Study: 28173843

Group type: EXPERIMENTAL
Intervention: Withdrawal of treatment (insulin pumps)
Number of subjects: 22
Study: 25060056

Group type: EXPERIMENTAL
Intervention: Ferric citrate
Number of subjects: 441

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 441
Study: 23939354

Group type: EXPERIMENTAL
Intervention: Face-to-face prompting of critical care physicians
Number of subjects: 296

Group type: COMPARATOR
Intervention: Unprompted electronic checklist
Number of subjects: 296
Study: 22108478

Group type: EXPERIMENTAL
Intervention: Pycnogenol® + ICS (100 mg daily, 50 mg in the morning and 50 mg in the evening)
Number of subjects: 76

Group type: COMPARATOR
Intervention: ICS only
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Pycnogenol® + ICS
Number of subjects: 76
Study: 18262445

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CE-US)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 2D time‐of‐flight magnetic resonance angiography (2D‐TOF MRA)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced magnetic resonance angiography (CE‐MRA)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 31
Study: 17017821

Group type: EXPERIMENTAL
Intervention: Selegiline transdermal system (STS) 6 mg/24 hours to 12 mg/24 hours
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study: 12705366

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (Lucrin) 3.75 mg administered s.c. monthly
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (healthy age and puberty matched girls)
Number of subjects: 44
Study: 10997967

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control (no cytoreductive therapy)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Busulphan plus Hydroxyurea (HU)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Hydroxyurea only
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: No chemotherapy
Number of subjects: 114
Study: 8774038

Group type: EXPERIMENTAL
Intervention: Different rates of force application (ramp)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Computer-mediated myometric procedure
Number of subjects: 24
Study: 1594210

Group type: EXPERIMENTAL
Intervention: Schocket shunt
Number of subjects: 0

Group type: COMPARATOR
Intervention: Molteno implant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study: 6690877

Group type: EXPERIMENTAL
Intervention: Second generation laryngeal prosthesis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Currently existing laryngeal prosthesis
Number of subjects: 0
Study: 31577727

Group type: EXPERIMENTAL
Intervention: Nomogram for overall survival (OS) prediction
Number of subjects: 3234

Group type: EXPERIMENTAL
Intervention: Nomogram for disease-specific survival (DSS) prediction
Number of subjects: 3234
Study: 26314821

Group type: EXPERIMENTAL
Intervention: Urticaria Patient Daily Diary (UPDD)
Number of subjects: 975
Study: 24279738

Group type: COMPARATOR
Intervention: Avocado Added (AA)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 26
Study: 21292847

Group type: EXPERIMENTAL
Intervention: 25% Calorie Restriction (CR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-Calorie Diet (LCD, 890 kcal/day until 15% weight loss, then weight maintenance)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10% Calorie Restriction (CR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30% Calorie Restriction (CR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 19994680

Group type: EXPERIMENTAL
Intervention: Acupuncture at Fengchi (GB 20) and 'Gongxue'
Number of subjects: 60

Group type: COMPARATOR
Intervention: Western medicine (Flunarizine hydrochlorid capsules)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 17341173

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation targeting the hemisphere where the stroke occurred to enhance cortical excitability.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation targeting the intact hemisphere to suppress cortical excitability.
Number of subjects: 0
Study: 15083779

Group type: EXPERIMENTAL
Intervention: Psoriasis patients
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: PASI components (desquamation on upper limbs)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: PASI components (desquamation on scalp)
Number of subjects: 85
Study: 11282668

Group type: EXPERIMENTAL
Intervention: Intranasal lidocaine (1 mL of 4% lidocaine)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 49
Study: 9919184

Group type: EXPERIMENTAL
Intervention: Aromatherapy and massage
Number of subjects: 0
Study: 8310996

Group type: EXPERIMENTAL
Intervention: 22-44 g pyruvate (n = 17)
Number of subjects: 34

Group type: COMPARATOR
Intervention: 18-35 g polyglucose (placebo, Polycose, n = 17)
Number of subjects: 34
Study: 3335988

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg metoclopramide orally, 40‐45 min before procedure
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo orally, 40‐45 min before procedure
Number of subjects: 18
Study: 31917874

Group type: EXPERIMENTAL
Intervention: Automatic lancet
Number of subjects: 105

Group type: COMPARATOR
Intervention: Needle
Number of subjects: 105